ストックスクリーナーアプリを入手
6.05
7.27%
0.41
プレマーケット:
6.09
0.04
+0.66%
前日終値:
$5.64
開ける：
$5.7
24時間の取引高:
18.04M
Relative Volume:
0.74
時価総額：
$5.96B
収益：
$1.31M
当期純損益:
$-597.65M
株価収益率:
-6.2371
EPS:
-0.97
ネットキャッシュフロー:
$-425.62M
1週間 パフォーマンス:
-3.20%
1か月 パフォーマンス:
+182.71%
6か月 パフォーマンス:
+154.20%
1年 パフォーマンス:
+82.78%
1日の値動き範囲:
$5.6101
$6.075
1週間の範囲:
$5.58
$6.75
52週間の値動き範囲:
$1.83
$8.28
Immunitybio Inc Stock (IBRX) Company Profile
Compare IBRX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
IBRX
Immunitybio Inc
|
6.05 | 5.56B | 1.31M | -597.65M | -425.62M | -0.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.92 | 116.41B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
785.51 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
811.45 | 50.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.16 | 43.76B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
353.92 | 38.40B | 4.98B | 69.60M | 525.67M | 0.5198 |
Immunitybio Inc Stock (IBRX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2025-03-06 | 開始されました | H.C. Wainwright | Buy |
| 2025-01-10 | 開始されました | BTIG Research | Buy |
| 2023-05-12 | ダウングレード | Piper Sandler | Overweight → Neutral |
| 2022-08-03 | 開始されました | Jefferies | Buy |
Immunitybio Inc (IBRX) 最新ニュース
New Sign-Off Propels ImmunityBio - Los Angeles Business Journal
Aug Ideas: Does ImmunityBio Inc have a competitive edgeOil Prices & Weekly Setup with ROI Potential - baoquankhu1.vn
ImmunityBio Inc. (IBRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
ImmunityBio initiates another cell therapy trial with no chemotherapy needs - MSN
ImmunityBio Accelerates Pipeline with New Lymphoma Trial Amid Stellar Revenue Forecast - AD HOC NEWS
Soon-Shiong, ImmunityBio Exit Challenge to Cancer Drug Financing - Bloomberg Law News
ImmunityBio Stockholder Targets Soon-Shiong In Chancery - Law360
ImmunityBio (NASDAQ:IBRX) Stock Price Up 3.3%Should You Buy? - MarketBeat
Soon-Shiong Defends ImmunityBio Financing Pact for Cancer Drug - Bloomberg Law News
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Bath & Body Works, Inc. of Class Action Lawsuit and Upcoming Deadlines – BBWI - GlobeNewswire Inc.
IBRX garners retail attention on positive update in immunotherapy for lung cancer patients - MSN
ImmunityBio Shares Maintain Upward Momentum on Clinical and Commercial Progress - AD HOC NEWS
BTIG Reaffirms Their Buy Rating on ImmunityBio (IBRX) - The Globe and Mail
ImmunityBio Stock Maintains Momentum with New Clinical Trial - AD HOC NEWS
ImmunityBio (NASDAQ:IBRX) Trading Down 1.9%Should You Sell? - MarketBeat
Immunitybio Initiates Another Cell Therapy Trial With No Chemotherapy Needs - Stocktwits
Piper Sandler see label expansion potential for ImmunityBio, Inc. (IBRX)’s Anktiva following Quilt data - MSN
Piper Sandler See Label Expansion Potential for ImmunityBio, Inc. (IBRX)’s ANKTIVA Following QUILT Data - Yahoo Finance
ImmunityBio Launches Phase 2 Study of Cell Therapy in Indolent Lymphomas - marketscreener.com
ImmunityBio launches phase 2 chemotherapy-free car-nk cell therapy trial with Anktiva - marketscreener.com
ImmunityBio launches phase 2 trial for chemotherapy-free lymphoma therapy - Investing.com
ImmunityBio Launches Phase 2 Chemotherapy-Free CAR-NK Cell Therapy Trial with ANKTIVA® (ResQ215B) in Indolent Lymphomas - Business Wire
ImmunityBio Stock: Commercialization Efforts Accelerate Following Key Approvals - AD HOC NEWS
ImmunityBio shares jump after constructive FDA talks on bladder cancer therapy - MSN
ImmunityBio stock jumps into the weekend as IBRX traders eye an FDA resubmission clock - TechStock²
ImmunityBio (IBRX) sheds 4% on profit-taking after 14-day run - MSN
Did ANKTIVA’s Expanding Approvals and Chemo‑Free GBM Data Just Shift ImmunityBio’s (IBRX) Investment Narrative? - Sahm
Biotech Stocks To Keep An Eye OnJanuary 31st - MarketBeat
Why ImmunityBio Inc. (IBRX) Went Down On Tuesday? - MSN
Clinical Promise and Regulatory Scrutiny Collide for ImmunityBio - AD HOC NEWS
ImmunityBio, Inc. (NASDAQ:IBRX) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
ImmunityBio Stock Surges on Clinical and Commercial Momentum - AD HOC NEWS
ImmunityBio stock rebounds: FDA scrutiny, a $505 million note and the next catalyst for IBRX - TechStock²
ImmunityBio (NASDAQ:IBRX) Trading Up 6.6%Here's Why - MarketBeat
ImmunityBio Stock Skyrockets Amid FDA Progress and Clinical Advances - StocksToTrade
MAHA Action Media Hub - ImmunityBio
Scrutiny Over FDA Communications Weighs on ImmunityBio Shares - AD HOC NEWS
IBRX stock gains pre-market after a volatile trading session following phase 2 glioblastoma trial update: Retail backs ImmunityBio’s cancer research - MSN
Lilly, Repertoire strike $2 billion autoimmune alliance - statnews.com
Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - marketscreener.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ImmunityBio, Inc.IBRX - PR Newswire
Brokers Offer Predictions for ImmunityBio FY2027 Earnings - MarketBeat
ImmunityBio’s Soon-Shiong mischaracterized talks with FDA over cancer drug, sources say - statnews.com
A High-Stakes Surge for ImmunityBio Shares - AD HOC NEWS
Positive Regulatory Developments and Stellar Growth for ImmunityBio - AD HOC NEWS
ImmunityBio Surges on Trial Success and Saudi FDA Approvals - timothysykes.com
ImmunityBio Stocks Surge Amid Clinical Advances and Strategic Growth - StocksToTrade
ImmunityBio (NASDAQ:IBRX) Shares Down 6%Should You Sell? - MarketBeat
Promising Biotech Stocks To ResearchJanuary 28th - MarketBeat
ImmunityBio (IBRX) Sheds 4% on Profit-Taking After 14-Day Run - Finviz
Late-Stage Breakthroughs: How 2026's Top Clinical Platforms Are Redefining Cancer Treatment - Investing News Network
Immunitybio Inc (IBRX) 財務データ
収益
当期純利益
現金流量
EPS
0.23%
1.25%
大文字化:
|
ボリューム (24 時間):